S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)

Johnson & Johnson Ordered to Pay $18.8 Million in Talc Cancer Suit


On Tuesday, John & Johnson (J&J) filed a lawsuit suing the Biden administration over Medicare's new authority to reduce drug prices, joining Merck and Bristol Myers Squibb in challenging the controversial provision of the Inflation Reduction Act.

The Inflation Reduction Act, signed into law in August 2022, aims to fight inflation, lower the deficit, and reduce carbon emissions, among other goals. It includes reforms to the tax system, investments in clean energy, and allows Medicare to negotiate prescription drug prices.

The lawsuit argues that the IRA Medicare price negotiations violate the First and Fifth Amendments of the U.S. Constitution by "coercing" the company into "agreeing" that the government is "negotiating" a "fair" price and compels the company "to make false and misleading statements," according to the complaint.

Additionally, the company believes that the IRA will stifle medical progress.

"We believe that the IRA's pricing provisions will constrain medical innovation, limit patient access and choice, and negatively impact the overall quality of patient care," J&J wrote in a press release on Tuesday.

The U.S. Health and Human Services Department said it will "vigorously defend the President's drug price negotiation law, which is already helping to lower health care costs for seniors and people with disabilities," per CNBC.

How Much Did J&J Pay for Talc Cancer Lawsuit?

Also on Tuesday, Johnson & Johnson (J&J) was ordered to pay $18.8 million to a California man who claimed he developed cancer from using the company's baby powder, Reuters reported.


Emory Hernandez Valadez, 24, filed a lawsuit last year against J&J claiming he developed mesothelioma due to prolonged exposure to the company's talc since childhood.

Related: Johnson & Johnson Ordered to Pay $55 Million in Talc-Powder Trial

Talc is a soft mineral used in various consumer products like baby powder and cosmetics for its ability to absorb moisture and reduce friction. However, its use has also been subject to controversy, particularly with J&J, which has faced thousands of lawsuits alleging its talc-based products are contaminated with cancer-causing asbestos.

In April, the company filed for bankruptcy through a subsidiary, LTL Management, with a proposal to settle over 38,000 lawsuits for $8.9 billion. However, most litigation has been halted during bankruptcy proceedings. The reason Hernandez's trial proceeded was due to his terminal condition and the rarity of his form of mesothelioma, setting it apart from the majority of cases against J&J, Reuters added.

The jury ruled in favor of Hernandez on Tuesday. While Hernandez was awarded damages for medical bills and strife, the jury did not grant punitive damages against J&J.

The company plans to appeal the verdict, maintaining that its products are safe and do not cause cancer, per Reuters.

Erik Haas, J&J vice president of litigation, told the outlet that the verdict is "irreconcilable with the decades of independent scientific evaluations confirming Johnson's Baby Powder is safe, does not contain asbestos, and does not cause cancer."

Related: Johnson & Johnson Hit With More Than $1 Billion Verdict on Hip Implants

→ Critical asset just had biggest fall on record (From Stansberry Research) (Ad)

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.9704 of 5 stars
$159.84-1.4%2.98%11.57Hold$177.31
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Stock Price at Critical Turning Point

Johnson & Johnson's Stock Price at Critical Turning Point

Johnson & Johnson had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales.

Search Headlines: